

\$350+ Million Vasculitis Treatment Market: Allied Market Research Reveals Growth Drivers and Key Segments by 2031

PORTLAND, OR, UNITED STATES, October 8, 2024 /EINPresswire.com/ -- The global <u>vasculitis</u> <u>treatment market</u> has witnessed substantial growth, reaching a value of \$250.1 million in 2021 and projected to grow to \$350.1 million by 2031 at a CAGR of 3.4%. Vasculitis, which refers to inflammation of blood vessels, affects arteries, veins, and capillaries, leading to a range of symptoms and health complications. This article highlights the key factors driving the growth of the vasculitis treatment market, its segmentation, and future opportunities.

000 0 00000 0000 00 0000 000000: https://www.alliedmarketresearch.com/request-sample/3523

Key Market Drivers

- Increasing Prevalence of Vasculitis: As vasculitis becomes more common, the demand for effective treatments rises, contributing significantly to market expansion.
- Growing Incidence of Chronic Diseases: The rise in chronic diseases such as rheumatoid arthritis and lupus has created a greater need for vasculitis treatments.
- Advancements in Biologic Therapies: Research and development in biologics, including drugs that regulate immune responses, are fueling market growth. Increased success rates in clinical trials have furthered the adoption of biologics.
- Surge in Use of Corticosteroids: The easy availability and effectiveness of corticosteroids have made them a primary treatment option, although their side effects are driving interest in alternative therapies like biologics.
- Rising Healthcare Access in Developing Countries: Growing awareness and better access to healthcare in developing regions have boosted the consumption of immunosuppressants and corticosteroids.

Market Restraints

- Side Effects of Corticosteroids: While corticosteroids are widely used, their potential side effects, including increased risk of infection and long-term health complications, could limit market growth.
- Impact of COVID-19: During the pandemic, market growth was slowed as patients turned to self-medication or delayed seeking medical care. However, recovery is expected as healthcare

systems stabilize.

Opportunities in the Vasculitis Treatment Market

- Adoption of Biologics: The increasing adoption of biologics, coupled with ongoing research, offers significant opportunities for growth.
- Emerging Markets: Countries in the Asia-Pacific region are experiencing increased investment in healthcare infrastructure, offering potential for market expansion.

Market Segmentation

1. By Drug Class:

- Biologics: Expected to witness the highest growth due to fewer side effects compared to corticosteroids.
- Corticosteroids & Immunosuppressants: Dominated the market in 2021 due to their costeffectiveness and widespread use.
- 2. By Disease Type:
- Small & Medium Vessel Vasculitis: This segment, including ANCA-associated vasculitis, held the largest market share in 2021 and is expected to grow further due to the higher incidence of related diseases.
- Large Vessel Vasculitis: A smaller but still significant segment of the market.

3. By Distribution Channel:

- Hospital Pharmacies: Held the majority market share in 2021, driven by the availability of high-cost drugs and reimbursement policies.
- Drug Store & Retail Pharmacies: Expected to grow at the highest CAGR due to ease of access and long-term treatment needs.
- Online Pharmacies: Gaining popularity as a convenient option for patients.

Regional Outlook

- North America: Dominated the market in 2021, largely due to advanced healthcare infrastructure and the presence of leading pharmaceutical companies.
- Asia-Pacific: Anticipated to experience the fastest growth, driven by healthcare developments, increased investments, and rising awareness.

The global vasculitis treatment market is poised for steady growth over the next decade, driven by increasing vasculitis cases, advancements in biologic treatments, and improved healthcare access in developing regions. While the widespread use of corticosteroids will continue to influence the market, the growing interest in biologics presents a promising future for more targeted and safer therapies.

000000 00000 000000: https://www.alliedmarketresearch.com/purchase-enquiry/3523

David Correa Allied Market Research

+1 800-792-5285 email us here Visit us on social media: Facebook Χ

This press release can be viewed online at: https://www.einpresswire.com/article/749928795

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.